Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885511 | 0.87 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3CAPIK3CBXIAP | |
| SCHEMBL2326527 | 0.85 | PIK3CD (0.65) | PIK3CDPIK3CGPIK3CAPIK3CBXIAP | |
| SCHEMBL13525246 | 0.84 | PIK3CD (0.57) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL1784761 | 0.84 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL1787009 | 0.84 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL1784745 | 0.84 | PIK3CD (0.57) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL48709 | 0.83 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL1783493 | 0.82 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL1784393 | 0.82 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL1882046 | 0.81 | PIK3CA (0.43) | PIK3CDPIK3CGPIK3CAPIK3CBXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK1 | PIK3CD 12/4885PIK3CG 6/4885PIK3CA 1/4885 |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK3 | PIK3CD 10/4885PIK3CG 6/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.